金河生物(002688.SZ):財富51號資管計劃減持期屆滿 擬繼續減持不超1%股份
格隆匯3月25日丨金河生物(002688.SZ)公佈,公司於2019年9月3日披露,股東上銀基金-浦發銀行-上銀基金財富51號資產管理計劃(以下簡稱“財富51號資管計劃”)因產品自身運作需要,計劃在該公告披露之日起15個交易日後的6個月內以集中競價交易方式減持的股份數量合計不超過1270.58萬股,佔公司總股本2%。
公司於2020年3月25日收到管理人上銀基金管理有限公司出具的《股東減持計劃期限屆滿暨下期減持計劃告知函》,獲悉其減持計劃期限屆滿並擬繼續減持公司股份,此次累計減持1268.34萬股,減持比例2.00%;減持後持有公司2737.57萬股,佔總股本的4.31%。
財富51號資管計劃擬實施下一期減持計劃,擬自減持計劃公告發布之日起十五個交易日之後的三個月內減持合計不超過635.2896萬股(不超過公司總股本1%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.